VOR - NASDAQ
Vor Biopharma Inc.
$13.44
-0.037%Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotVor Biopharma Inc. Management Team
Ms. Tania Philipp
Chief People Officer
Ms. Amy Quinlan
Interim Principal Accounting Officer
Dr. Robert Ang M.B.A., M.D., MBBS
President, Chief Executive Officer & Director
Compensation
$994,049
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D.
Scientific Founder & Chairman of Scientific Advisory Board
Mr. David Phillips M.B.A.
Senior Vice President & Head of Quality
Vor Biopharma Inc. Insider Positioning
During the last 12 months, insiders have purchased $74.39M and sold $62.56M worth of VOR shares, resulting in $11.83M of net buying activity.
3 Months
0
0.00
2.1M
35.14M
-35.1M
-$35.14M
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
10.1M
257.60K
3.2M
20.39M
-20.1M
-$20.13M
9-12 Months
83.3M
74.13M
3.5M
7.03M
+67.1M
+$67.11M
Top Buyers
Kress Jean-Paul
Director, Officer: Ceo And Chairman
$74.13M
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$139K
Reed Sarah Burgess
Director
$119K
Top Sellers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$44.55M
Reprogrammed Interchange Llc
10 Percent Owner
$18.01M
Insider Activity Analysis
Net Insider Sentiment
Moderately bullish with $11.83M net buying. Insiders show cautious optimism through measured share purchases.
Buy/Sell Ratio
Positive buy/sell ratio. Buying exceeds or matches selling, indicating net positive insider sentiment.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
3 insider buyers vs. 2 sellers. More insiders buying than selling indicates positive sentiment.
Insider Activity Insight
Broad-based insider buying: When multiple insiders independently decide to purchase shares, it often reflects genuine confidence rather than coordinated optics. This pattern deserves attention, especially if buying followed a price decline.
SEC Filings
VOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 23, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | August 08, 2025 | August 25, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | April 08, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 09, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 14, 2023 | May 26, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 28, 2022 | June 14, 2022 | 2022 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.